Reparixin, a clinical-grade CXCR1/2 inhibitor, was reported to reduce the malignant features of human pancreatic cancer cells via inhibiting IL-8-CXCR1/2 signaling (26) In preclinical colon cancer models, the combination of the CXCR1/2 small molecule antagonist SCH-527123 and oxaliplatin resulted in greater reductions in cell proliferation, tumor growth, apoptosis, and angiogenesis than in monotherapy (27). Here, CXCR1 is linked to colonic neoplasm.